We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BioMarin Stops Development of DMD Drug Following EMA Rejection
BioMarin Stops Development of DMD Drug Following EMA Rejection
BioMarin is calling it quits for its Duchenne muscular dystrophy candidate and three related products in its pipeline after the EMA’s Committee for Medicinal Products for Human Use signaled that it would not back the candidate.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor